XML 46 R32.htm IDEA: XBRL DOCUMENT v3.21.2
STOCK-BASED COMPENSATION (Tables)
6 Months Ended
Jun. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of non-cash compensation expense related to equity awards
Non-cash compensation related to equity awards is included in the following line items in the accompanying consolidated statements of operations and comprehensive income (in thousands):
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2021202020212020
Cost of revenue$463 $333 $860 $575 
Selling and marketing expense1,976 1,597 3,778 2,753 
General and administrative expense13,254 9,729 25,425 18,852 
Product development2,601 1,499 4,667 2,895 
Total non-cash compensation$18,294 $13,158 $34,730 $25,075 
Summary of changes in outstanding stock options
A summary of changes in outstanding stock options is as follows:
 Number of OptionsWeighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value(a)
  (per option)(in years)(in thousands)
Options outstanding at January 1, 2021924,710 $111.82 
Granted (b)
69,258 243.71 
Exercised(156,113)7.17 
Forfeited(4,727)263.72 
Expired(35)371.25 
Options outstanding at June 30, 2021833,093 141.52 5.20$82,110 
Options exercisable at June 30, 2021543,666 $71.06 3.20$82,039 
(a)The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company's closing stock price of $211.88 on the last trading day of the quarter ended June 30, 2021 and the exercise price, multiplied by the number of shares covered by in-the-money options) that would have been received by the option holder had the option holder exercised these options on June 30, 2021. The intrinsic value changes based on the market value of the Company's common stock.
(b)During the six months ended June 30, 2021, the Company granted stock options to certain employees and members of the board of directors with a weighted average grant date fair value per share of $130.25, calculated using the Black-Scholes option pricing model, which vesting periods include (a) immediate vesting on grant date (b) earlier of one year from grant date and the Company's annual meeting of stockholders for 2022 and (c) three years from grant date.
For purposes of determining stock-based compensation expense, the weighted average grant date fair value per share of the stock options was estimated using the Black-Scholes option pricing model, which requires the use of various key assumptions. The weighted average assumptions used are as follows:
Expected term (1)
5.00 - 6.00 years
Expected dividend (2)
— 
Expected volatility (3)
53 - 59%
Risk-free interest rate (4)
0.59 - 1.07%
(1)The expected term of stock options granted was calculated using the "Simplified Method," which utilizes the midpoint between the weighted average time of vesting and the end of the contractual term. This method was utilized for the stock options due to a lack of historical exercise behavior by the Company's employees.
(2)For all stock options granted in 2021, no dividends are expected to be paid over the contractual term of the stock options, resulting in a zero expected dividend rate.
(3)The expected volatility rate is based on the historical volatility of the Company's common stock.
(4)The risk-free interest rate is specific to the date of grant. The risk-free interest rate is based on U.S. Treasury yields for notes with comparable expected terms as the awards, in effect at the grant date.
Schedule of stock option valuation assumptions
For purposes of determining stock-based compensation expense, the weighted average grant date fair value per share of the stock options was estimated using the Black-Scholes option pricing model, which requires the use of various key assumptions. The weighted average assumptions used are as follows:
Expected term (1)
5.00 - 6.00 years
Expected dividend (2)
— 
Expected volatility (3)
53 - 59%
Risk-free interest rate (4)
0.59 - 1.07%
(1)The expected term of stock options granted was calculated using the "Simplified Method," which utilizes the midpoint between the weighted average time of vesting and the end of the contractual term. This method was utilized for the stock options due to a lack of historical exercise behavior by the Company's employees.
(2)For all stock options granted in 2021, no dividends are expected to be paid over the contractual term of the stock options, resulting in a zero expected dividend rate.
(3)The expected volatility rate is based on the historical volatility of the Company's common stock.
(4)The risk-free interest rate is specific to the date of grant. The risk-free interest rate is based on U.S. Treasury yields for notes with comparable expected terms as the awards, in effect at the grant date.
Schedule of changes in outstanding stock options with market conditions
A summary of changes in outstanding stock options with market conditions at target is as follows:
 Number of Options with Market ConditionsWeighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value(a)
  (per option)(in years)(in thousands)
Options outstanding at January 1, 2021700,209 $236.01 
Granted— — 
Exercised— — 
Forfeited— — 
Expired— — 
Options outstanding at June 30, 2021700,209 236.01 7.25$11,308 
Options exercisable at June 30, 2021 $ 0.00$ 
(a)The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company's closing stock price of $211.88 on the last trading day of the quarter ended June 30, 2021 and the exercise price, multiplied by the number of shares covered by in-the-money options) that would have been received by the option holder had the option holder exercised these options on June 30, 2021. The intrinsic value changes based on the market value of the Company's common stock.
Schedule of changes in outstanding non-vested RSUs and restricted stock
A summary of changes in outstanding nonvested restricted stock units ("RSUs") is as follows:
 RSUs
 Number of UnitsWeighted Average Grant Date Fair Value
(per unit)
Nonvested at January 1, 2021194,686 $289.82 
Granted149,259 245.00 
Vested(54,644)290.38 
Forfeited(20,735)269.88 
Nonvested at June 30, 2021268,566 $266.34 
Schedule of changes in outstanding nonvested RSUs and restricted stock with performance and market conditions
A summary of changes in outstanding nonvested RSUs with performance conditions is as follows:
 RSUs with Performance Conditions
 Number of UnitsWeighted Average Grant Date Fair Value
(per unit)
Nonvested at January 1, 20216,328 $223.90 
Granted— — 
Vested— — 
Forfeited— — 
Nonvested at June 30, 20216,328 $223.90 
A summary of changes in outstanding nonvested restricted stock awards ("RSAs") with performance conditions is as follows:
 RSAs with Performance Conditions
 Number of AwardsWeighted Average Grant Date Fair Value
(per unit)
Nonvested at January 1, 202123,804 $340.25 
Granted— — 
Vested(11,902)340.25 
Forfeited— — 
Nonvested at June 30, 202111,902 $340.25 
A summary of changes in outstanding nonvested RSAs with market conditions at target is as follows:
 RSAs with Market Conditions
 Number of AwardsWeighted Average Grant Date Fair Value
(per unit)
Nonvested at January 1, 202126,674 $340.25 
Granted— — 
Vested— — 
Forfeited— — 
Nonvested at June 30, 202126,674 $340.25